Skip to main content

INTERACTOMICA DISEÑO DE SONDAS E IMAGEN DE CARBOXIPEPTIDASAS. EN TRANSITO DE LA FUNCION A LA APLICABILIDAD

BIO2013-44973-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Substrate specificity of human metallocarboxypeptidase D: Comparison of the two active carboxypeptidase domains

  • García Pardo, Javier
  • Tanco, Sebastián Martín
  • Díaz, Lucía
  • Dasgupta, Sayani
  • Fernández Recio, Juan
  • Lorenzo, Júlia
  • Avilés, Francesc Xavier
  • Fricker, Lloyd D.
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi network that cycles to the cell surface through exocytic and endocytic pathways. Unlike other members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three carboxypeptidase-like domains, although only the first two domains are predicted to be enzymatically active. To investigate the enzymatic properties of each domain in human CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all three domains intact displays >50% activity from pH 5.0 to 7.5 with a maximum at pH 6.5, as does CPD with mutation of domain I. In contrast, the domain II mutant displayed >50% activity from pH 6.5-7.5. CPD with mutations in both domains I and II was completely inactive towards all substrates and at all pH values. A quantitative peptidomics approach was used to compare the activities of CPD domains I and II towards a large number of peptides. CPD cleaved C-terminal Lys or Arg from a subset of the peptides. Most of the identified substrates of domain I contained C-terminal Arg, whereas comparable numbers of Lys- and Arg-containing peptides were substrates of domain II. We also report that some peptides with C-terminal basic residues were not cleaved by either domain I or II, showing the importance of the P1 position for CPD activity. Finally, the preference of domain I for C-terminal Arg was validated through molecular docking experiments. Together with the differences in pH optima, the different substrate specificities of CPD domains I and II allow the enzyme to perform distinct functions in the various locations within the cell., This work was funded by the Spanish Ministry of Innovation and Competitiveness grants BIO2013-44973-R and BIO2016-78057-R (to FXA), by Plan Estatal grant number BIO2016-79960-R from the Spanish Ministry of Economy and Competitiveness (to JFR), and by grant R01-DA004494 from the United States’ National Institute of Health (to LDF).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pt(IV)-based nanoscale coordination polymers: Antitumor activity, cellular uptake and interactions with nuclear DNA

  • Adarsh, Nayarassery N.
  • Frias, Carolina
  • Ponnoth Lohidakshan, T. M.
  • Lorenzo, Julia
  • Novio, Fernando
  • García-Pardo, Javier
  • Ruiz Molina, Daniel
Cisplatin has been for many years the gold standard chemotherapeutic drug for the treatment of a wide range of solid tumors, even though its use is commonly associated with serious side effects including non-selective toxicity, myelosuppression or development of cisplatin resistance, among others complications. Over the last decade, a number of nanoparticle formulations were developed to reduce its side effects and improve the selectivity and efficacy of this drug. In this study, we have developed a novel nanoparticle platform based on nanoscale coordination polymer named (Zn-Pt(IV)-NCPs) which contains a Pt(IV) prodrug, Zn and the linker ligand 1,4-Bis(imidazol-1-ylmethyl)benzene (bix). The main objective has been to gain insights into the mechanism of action of this nanostructured material in comparison with cisplatin and the free Pt(IV) prodrug in order to establish a correlation between nanostructuration and therapeutic activity. Zn-Pt(IV)-NCPs nanoparticles displayed an average size close to 200 nm as determined by DLS, a good stability in physiologic environments, and a controlled drug release of Pt. In vitro studies demonstrated that Pt(IV)-NCPs showed an enhanced cytotoxic effect against cell culture of cervical cancer, neuroblastoma and human adenocarcinoma cells in comparison with free Pt(IV) prodrug. Although no difference in cell uptake of Pt was observed for any of the three cell lines assayed, a higher amount of Pt bound to the DNA was found in the cells treated with the nanostructured Pt(IV) prodrug. These studies suggest that the nanostructuration of the prodrug facilitate its activation and induce a change in the mechanism of action related to an increased interaction with the DNA as corroborated by the studies of direct interaction of the Pt(IV) prodrug, nanostructured or not, with DNA., This work was supported by project MAT2012-38318-C03-02, MAT2015-70615-R, BIO2013-44973-R and BIO2016-78057-R from the Spanish Government and by FEDER – European Commission funds. ICN2 acknowledges support from the Severo Ochoa Programme of the Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Grant SEV-2013-0295). The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. Authors would also like to acknowledge the support of the TRANSAUTOPHAGY COST Action, CA15138. NNA thanks the EU for a Marie Curie Intra-European Fellowship (FP6-MC-IEF-629703)., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Substrate specificity of human metallocarboxypeptidase D: Comparison of the two active carboxypeptidase domains

  • García-Pardo, Javier
  • Tanco, Sebastian
  • Diaz, Lucia
  • Dasgupta, Sayani
  • Fernandez-Recio, Juan
  • Lorenzo, Julia
  • Aviles, Francesc X.
  • Fricker, Lloyd D.
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi network that cycles to the cell surface through exocytic and endocytic pathways. Unlike other members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three carboxypeptidase-like domains, although only the first two domains are predicted to be enzymatically active. To investigate the enzymatic properties of each domain in human CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all three domains intact displays >50% activity from pH 5.0 to 7.5 with a maximum at pH 6.5, as does CPD with mutation of domain I. In contrast, the domain II mutant displayed >50% activity from pH 6.5–7.5. CPD with mutations in both domains I and II was completely inactive towards all substrates and at all pH values. A quantitative peptidomics approach was used to compare the activities of CPD domains I and II towards a large number of peptides. CPD cleaved C-terminal Lys or Arg from a subset of the peptides. Most of the identified substrates of domain I contained C-terminal Arg, whereas comparable numbers of Lys- and Arg-containing peptides were substrates of domain II. We also report that some peptides with C-terminal basic residues were not cleaved by either domain I or II, showing the importance of the P1 position for CPD activity. Finally, the preference of domain I for C-terminal Arg was validated through molecular docking experiments. Together with the differences in pH optima, the different substrate specificities of CPD domains I and II allow the enzyme to perform distinct functions in the various locations within the cell., This work was funded by the Spanish Ministry of Innovation and Competitiveness grants BIO2013-44973-R and BIO2016-78057-R (to FXA), by Plan Estatal grant number BIO2016-79960-R from the Spanish Ministry of Economy and Competitiveness (to JFR), and by grant R01-DA004494 from the United States’ National Institute of Health (to LDF)., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Substrate specificity of human metallocarboxypeptidase D: Comparison of the two active carboxypeptidase domains

  • García Pardo, Javier
  • Tanco, Sebastián Martín
  • Díaz, Lucía
  • Dasgupta, Sayani
  • Fernández Recio, Juan
  • Lorenzo, Júlia
  • Avilés, Francesc Xavier
  • Fricker, Lloyd D.
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi network that cycles to the cell surface through exocytic and endocytic pathways. Unlike other members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three carboxypeptidase-like domains, although only the first two domains are predicted to be enzymatically active. To investigate the enzymatic properties of each domain in human CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all three domains intact displays >50% activity from pH 5.0 to 7.5 with a maximum at pH 6.5, as does CPD with mutation of domain I. In contrast, the domain II mutant displayed >50% activity from pH 6.5-7.5. CPD with mutations in both domains I and II was completely inactive towards all substrates and at all pH values. A quantitative peptidomics approach was used to compare the activities of CPD domains I and II towards a large number of peptides. CPD cleaved C-terminal Lys or Arg from a subset of the peptides. Most of the identified substrates of domain I contained C-terminal Arg, whereas comparable numbers of Lys- and Arg-containing peptides were substrates of domain II. We also report that some peptides with C-terminal basic residues were not cleaved by either domain I or II, showing the importance of the P1 position for CPD activity. Finally, the preference of domain I for C-terminal Arg was validated through molecular docking experiments. Together with the differences in pH optima, the different substrate specificities of CPD domains I and II allow the enzyme to perform distinct functions in the various locations within the cell., This work was funded by the Spanish Ministry of Innovation and Competitiveness grants BIO2013-44973-R and BIO2016-78057-R (to FXA), by Plan Estatal grant number BIO2016-79960-R from the Spanish Ministry of Economy and Competitiveness (to JFR), and by grant R01-DA004494 from the United States’ National Institute of Health (to LDF).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Substrate specificity of human metallocarboxypeptidase D: Comparison of the two active carboxypeptidase domains

  • García-Pardo, Javier
  • Tanco, Sebastian
  • Diaz, Lucia
  • Dasgupta, Sayani
  • Fernandez-Recio, Juan
  • Lorenzo, Julia
  • Aviles, Francesc X.
  • Fricker, Lloyd D.
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi network that cycles to the cell surface through exocytic and endocytic pathways. Unlike other members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three carboxypeptidase-like domains, although only the first two domains are predicted to be enzymatically active. To investigate the enzymatic properties of each domain in human CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all three domains intact displays >50% activity from pH 5.0 to 7.5 with a maximum at pH 6.5, as does CPD with mutation of domain I. In contrast, the domain II mutant displayed >50% activity from pH 6.5–7.5. CPD with mutations in both domains I and II was completely inactive towards all substrates and at all pH values. A quantitative peptidomics approach was used to compare the activities of CPD domains I and II towards a large number of peptides. CPD cleaved C-terminal Lys or Arg from a subset of the peptides. Most of the identified substrates of domain I contained C-terminal Arg, whereas comparable numbers of Lys- and Arg-containing peptides were substrates of domain II. We also report that some peptides with C-terminal basic residues were not cleaved by either domain I or II, showing the importance of the P1 position for CPD activity. Finally, the preference of domain I for C-terminal Arg was validated through molecular docking experiments. Together with the differences in pH optima, the different substrate specificities of CPD domains I and II allow the enzyme to perform distinct functions in the various locations within the cell., This work was funded by the Spanish Ministry of Innovation and Competitiveness grants BIO2013-44973-R and BIO2016-78057-R (to FXA), by Plan Estatal grant number BIO2016-79960-R from the Spanish Ministry of Economy and Competitiveness (to JFR), and by grant R01-DA004494 from the United States’ National Institute of Health (to LDF)., Peer Reviewed, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The cytosolic carboxypeptidases CCP2 and CCP3 catalyze posttranslational removal of acidic amino acids

  • Tort Regàs, Olívia
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Rocha, Cecilia
  • Bièche, Ivan
  • Seixas, Cecilia
  • Bosc, Christophe
  • Andrieux, Annie
  • Moutin, Marie-Jo
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Janke, Carsten
The posttranslational modification of carboxy-terminal tails of tubulin plays an important role in the regulation of the microtubule cytoskeleton. Enzymes responsible for deglutamylating tubulin have been discovered within a novel family of mammalian cytosolic carboxypeptidases. The discovery of these enzymes also revealed the existence of a range of other substrates that are enzymatically deglutamylated. Only four of six mammalian cytosolic carboxypeptidases had been enzymatically characterized. Here we complete the functional characterization of this protein family by demonstrating that CCP2 and CCP3 are deglutamylases, with CCP3 being able to hydrolyze aspartic acids with similar efficiency. Deaspartylation is a novel posttranslational modification that could, in conjunction with deglutamylation, broaden the range of potential substrates that undergo carboxy-terminal processing. In addition, we show that CCP2 and CCP3 are highly regulated proteins confined to ciliated tissues. The characterization of two novel enzymes for carboxy-terminal protein modification provides novel insights into the broadness of this barely studied process.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of tight-binding plasmepsin II and falcipain 2 inhibitors in aqueous extracts of marine invertebrates by the combination of enzymatic and interaction-based assays

  • Salas-Sarduy, Emir
  • Guerra, Yasel
  • Covaleda Cortés, Giovanni|||0000-0002-7621-852X
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Chávez Planes, María A.
Natural products from marine origin constitute a very promising and underexplored source of interesting compounds for modern biotechnological and pharmaceutical industries. However, their evaluation is quite challenging and requires specifically designed assays to reliably identify the compounds of interest in a highly heterogeneous and interfering context. In the present study, we describe a general strategy for the confident identification of tight-binding protease inhibitors in the aqueous extracts of 62 Cuban marine invertebrates, using Plasmodium falciparum hemoglobinases Plasmepsin II and Falcipain 2 as model enzymes. To this end, we first developed a screening strategy that combined enzymatic with interaction-based assays and then validated screening conditions using five reference extracts. Interferences were evaluated and minimized. The results from the massive screening of such extracts, the validation of several hits by a variety of interaction-based assays and the purification and functional characterization of PhPI, a multifunctional and reversible tight-binding inhibitor for Plasmepsin II and Falcipain 2 from the gorgonian Plexaura homomalla, are presented.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dual T1/T2 MRI contrast agent based on hybrid SPION@coordination polymer nanoparticles

  • Borges, M.
  • Yu, Si-Ming
  • Laromaine, Anna|||0000-0002-4764-0780
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Suárez García, Salvio|||0000-0002-4156-0579
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Novio, Fernando|||0000-0002-1517-3612
We report a novel hybrid T /T dual MRI contrast agent by the encapsulation of SPIONs (T contrast agent) into an iron-based coordination polymer with T -weighted signal. This new hybrid material presents improved relaxometry and low cytotoxicity, which make it suitable for its use as contrast agent for MRI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization, Recombinant Production and Structure-Function Analysis of NvCI, A Picomolar Metallocarboxypeptidase Inhibitor from the Marine Snail Nerita versicolor

  • Covaleda Cortés, Giovanni|||0000-0002-7621-852X
  • Hernández, Martha
  • Trejo, Sebastián A.|||0000-0003-2866-5613
  • Mansur, Manuel
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Vendrell Roca, Josep|||0000-0002-9378-4742
  • Chávez Planes, María A.
  • Alonso del Rivero, Maday|||0000-0003-1988-6852
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
A very powerful proteinaceous inhibitor of metallocarboxypeptidases has been isolated from the marine snail Nerita versicolor and characterized in depth. The most abundant of four, very similar isoforms, NvCla, was taken as reference and N-terminally sequenced to obtain a 372-nucleotide band coding for the protein cDNA. The mature protein contains 53 residues and three disulphide bonds. NvCIa and the other isoforms show an exceptionally high inhibitory capacity of around 1.8 pM for human Carboxypeptidase A1 (hCPA1) and for other A-like members of the M14 CPA subfamily, whereas a twofold decrease in inhibitory potency is observed for carboxypeptidase B-like members as hCPB and hTAFIa. A recombinant form, rNvCI, was produced in high yield and HPLC, mass spectrometry and spectroscopic analyses by CD and NMR indicated its homogeneous, compact and thermally resistant nature. Using antibodies raised with rNvCI and histochemical analyses, a preferential distribution of the inhibitor in the surface regions of the animal body was observed, particularly nearby the open entrance of the shell and gut, suggesting its involvement in biological defense mechanisms. The properties of this strong, small and stable inhibitor of metallocarboxypeptidases envisage potentialities for its direct applicability, as well as leading or minimized forms, in biotechnological/biomedical uses.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pt(IV)-based nanoscale coordination polymers, antitumor activity, cellular uptake and interactions with nuclear DNA

  • Adarsh, Nayarassery N.|||0000-0003-2262-8512
  • Frias Botella, Carolina|||0000-0002-2393-707X
  • Ponnoth Lohidakshan, T. M.
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Cisplatin has been for many years the gold standard chemotherapeutic drug for the treatment of a wide range of solid tumors, even though its use is commonly associated with serious side effects including non-selective toxicity, myelosuppression or development of cisplatin resistance, among others complications. Over the last decade, a number of nanoparticle formulations were developed to reduce its side effects and improve the selectivity and efficacy of this drug. In this study, we have developed a novel nanoparticle platform based on nanoscale coordination polymer named (Zn-Pt(IV)-NCPs) which contains a Pt(IV) prodrug, Zn and the linker ligand 1,4-Bis(imidazol-1-ylmethyl)benzene (bix). The main objective has been to gain insights into the mechanism of action of this nanostructured material in comparison with cisplatin and the free Pt(IV) prodrug in order to establish a correlation between nanostructuration and therapeutic activity. Zn-Pt(IV)-NCPs nanoparticles displayed an average size close to 200 nm as determined by DLS, a good stability in physiologic environments, and a controlled drug release of Pt. In vitro studies demonstrated that Pt(IV)-NCPs showed an enhanced cytotoxic effect against cell culture of cervical cancer, neuroblastoma and human adenocarcinoma cells in comparison with free Pt(IV) prodrug. Although no difference in cell uptake of Pt was observed for any of the three cell lines assayed, a higher amount of Pt bound to the DNA was found in the cells treated with the nanostructured Pt(IV) prodrug. These studies suggest that the nanostructuration of the prodrug facilitate its activation and induce a change in the mechanism of action related to an increased interaction with the DNA as corroborated by the studies of direct interaction of the Pt(IV) prodrug, nanostructured or not, with DNA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Substrate specificity of human metallocarboxypeptidase D, comparison of the two active carboxypeptidase domains

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Díaz, Lucía
  • Dasgupta, Sayani
  • Fernández-Recio, Juan|||0000-0002-3986-7686
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Fricker, Lloyd D.
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi network that cycles to the cell surface through exocytic and endocytic pathways. Unlike other members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three carboxypeptidase-like domains, although only the first two domains are predicted to be enzymatically active. To investigate the enzymatic properties of each domain in human CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all three domains intact displays.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasticity in the Oxidative Folding Pathway of the High Affinity Nerita Versicolor Carboxypeptidase Inhibitor (NvCI)

  • Esperante, Sebastián|||0000-0002-5778-6871
  • Bronsoms, Sílvia|||0000-0001-9763-762X
  • Covaleda Cortés, Giovanni|||0000-0002-7621-852X
  • Trejo, Sebastián A.|||0000-0003-2866-5613
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Ventura, Salvador|||0000-0002-9652-6351
Nerita Versicolor carboxypeptidase inhibitor (NvCI) is the strongest inhibitor reported so far for the M14A subfamily of carboxypeptidases. It comprises 53 residues and a protein fold composed of a two-stranded antiparallel β sheet connected by three loops and stabilized by three disulfide bridges. Here we report the oxidative folding and reductive unfolding pathways of NvCI. Much debate has gone on whether protein conformational folding guides disulfide bond formation or instead they are disulfide bonds that favour the arrangement of local or global structural elements. We show here that for NvCI both possibilities apply. Under physiological conditions, this protein folds trough a funnelled pathway involving a network of kinetically connected native-like intermediates, all sharing the disulfide bond connecting the two β-strands. In contrast, under denaturing conditions, the folding of NvCI is under thermodynamic control and follows a "trial and error" mechanism, in which an initial quasi-stochastic population of intermediates rearrange their disulfide bonds to attain the stable native topology. Despite their striking mechanistic differences, the efficiency of both folding routes is similar. The present study illustrates thus a surprising plasticity in the folding of this extremely stable small disulfide-rich inhibitor and provides the basis for its redesign for biomedical applications.